- 询价
- 2025年11月24日
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 物种来源：
人
- 是否是肿瘤细胞：
0
- 细胞类型：
B淋巴细胞
- 器官来源：
脾
- 免疫类型：
IgM
- 细胞形态：
淋巴样
- 库存：
大量
- 生长状态：
悬浮生长
- ATCC Number：
CRL-8753™
- 运输方式：
冻存运输
| Designations: | C5B7 | ||
| Depositors: | Miles Inc., Genetics Systems Corporation | ||
| Isotype: | IgM | ||
| Biosafety Level: | 2 [Cells Contain HERPESVIRUS ] | ||
| Shipped: | frozen | ||
| Medium & Serum: | See Propagation | ||
| Growth Properties: | suspension | ||
| Organism: | Homo sapiens | ||
| Morphology: | lymphoblast |
||
| Source: | Organ: spleen Cell Type: B lymphocyte; Epstein-Barr virus (EBV) transformed |
||
| Cellular Products: | immunoglobulin; monoclonal antibody; against Pseudomonas aeruginosa lipopolysaccharide (LPS) of Fisher immunotype 1 (IATS type 6) | ||
| Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | ||
| Comments: | B cells obtained from a patient with cystic fibrosis (whose serum contained above normal titer to P. aeruginosa) were transformed with Epstein-Barr virus (EBV). The antibody is specific for the lipopolysaccharide of the Fisher immunotype 1 of P. aeruginosa. |
||
| Propagation: | ATCC complete growth medium: Iscove's modified Dulbecco's medium with 2 mM L-glutamine, 85%; heat-inactivated fetal bovine serum, 15% Temperature: 37.0°C Atmosphere: air, 95%; carbon dioxide (CO2), 5% |
||
| Subculturing: | Medium Renewal: Every 3 to 4 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
||
| Preservation: | Freeze medium: complete growth medium, 95%; DMSO, 5% | ||
| Doubling Time: | 24 to 36 hrs | ||
| References: | 3862: Siadak AW, Lostrom ME. Human monoclonal antibodies to serotypic lipopolysaccharide determinants on Gram-negative bacteria and their production. US Patent 4,834,975 dated May 30 1989 | ||
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验补体成分 C5(C5a/C5b) 补体成分：C5 血清浓度(μg/ml)：70 分子量(kDa)：190 亚单位(链)及分子量(kDa)：α∶115；β∶75 激活产物：C5a；C5b 生物学活性：C5a 强的过敏毒素作用、趋化作用、促代谢作用及免疫调节作用 C5b
Quantification of Complement C5b-9 Binding to Cells by Flow Cytometry
Interaction of the complement system, directly or indirectly (e.g., via antibodies), with cells activates the early and late complement components and culminates in the deposition of a membrane-spanning C5b-9 complex on the cell surface
8 色多重荧光免疫组化方法揭示补体在早期类风湿关节炎发展中的作用
2. 相关性/气泡图显示治疗后 48 种补体和 FcgR 基因的滑膜和血液基因表达，以及通过 DAS28-ESR 测量的基线和 6 个月时疾病活动度变化的相关性。 使用早期 RA 活检样本进行组织病理学和免疫组织化学研究以优化补体蛋白的检测。通过H&E和免疫组化IHC, 确认滑膜活检中存在七种补体蛋白和复合物，即 C3c、CFHR4、CFB、CFH、FCN3、MBL2 和 C5b-9 (MAC), 证实在 mRNA 分析中鉴定的个体补体蛋白确实在早期 RA 患者的滑膜中表达，因此可能在关节局部在关节
技术资料暂无技术资料 索取技术资料
